EU court adviser backs Illumina's appeal against EU antitrust regulators' review of $7.1bn Grail deal.

EU court adviser backs Illumina in challenge against EU antitrust regulators' review of $7.1bn Grail deal. The European Union's Court of Justice was urged to support U.S. gene sequencing company Illumina's appeal against the EU antitrust regulators' review of its $7.1bn bid for cancer test maker Grail, according to an adviser to the court. The EU antitrust regulators have previously vetoed the deal and ordered Illumina to unwind the transaction.